Study period | ||||||
---|---|---|---|---|---|---|
Enrollment | Treatment | Follow-up | ||||
Time point | Day 0 | Day 4 after the onset | Day 10 after the onset | Day 11 after the onset | Day 30 after the onset | Days 31–45 after the onset |
Enrollment | ||||||
Eligibility screen | ● | |||||
Informed consent | ● | |||||
Date collection | ● | |||||
Measurement | ● | |||||
Randomization | ● | |||||
Allocation | ● | |||||
Intervention | Acute phase | Recovery phase | Follow-up period | |||
Control group | Oral prednisone tablets | Stop taking prednisone and turn to electroacupuncture therapy | No intervention | |||
Experimental group | Oral prednisone tablets combined with electroacupuncture | |||||
Assessment | ||||||
SFGS | ● | ● | ● | ● | ||
H-B | ● | ● | ● | |||
NRS | ● | ● | ● | |||
FDI | ● | ● | ||||
MRI | ● | ● | ||||
sEMG | ● | ● | ||||
Adverse event | ● | ● | ● | ● |